






IN THE CLAIMS

1. (Previously presented) A method of providing a medical therapeutic treatment of Alzheimer's disease comprising administering to a human suffering from Alzheimer's disease a therapeutically effective amount of an endothelin antagonist selected from the group consisting of






$R = \text{CH}_2\text{CO}_2\text{H}$ or $\text{CH}_2\text{CH}_2\text{OH}$,




$X = \text{H}_2$ and $Y = \text{CH}_2$, or


$X = \text{O}$ and $Y = \text{O}$,




,




,




,




,




,






,






,




,





, and



2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Currently amended) The method of claim 1 wherein the endothelin antagonist ~~comprises~~ is bosentan.

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Previously presented) The method of claim 1 further comprising administering a therapeutically effective amount of a cholinesterase inhibitor useful in the medical therapeutic treatment of Alzheimer's disease.

14. (Cancelled)

15. (Previously presented) The method of claim 13 wherein the cholinesterase inhibitor is selected from the group consisting of tacrine, metrifonate, bethanacol, physostigmine, donepezil, rivastigmine, galantamine, and mixtures thereof.

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Previously presented) The method of claim 13 wherein the endothelin antagonist and the cholinesterase inhibitor are administered simultaneously.

20. (Previously presented) The method of claim 13 wherein the endothelin antagonist and the cholinesterase inhibitor are administered from a single composition.

21. (Previously presented) The method of claim 13 wherein the endothelin antagonist and the cholinesterase inhibitor are administered from separate compositions.

22. (Previously presented) The method of claim 13 wherein the endothelin antagonist and the cholinesterase inhibitor are administered separately.

23. (Previously presented) The method of claim 22 wherein the endothelin antagonist is administered prior to the cholinesterase inhibitor.

24. (Previously presented) The method of claim 22 wherein the endothelin antagonist is administered after the cholinesterase inhibitor.

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

Application No. 10/659,579
Amendment dated May 15, 2008
Reply to Office Action of December 20, 2007

Docket No.: 27611/38545A

29. (Cancelled)

30. (Cancelled)